As Methylene Blue Goes Mainstream, Vancouver Company Sets a Transparency Standard Most Brands Cannot Match
VANCOUVER, BC – July 14, 2026 – Methylene blue has gone from a niche biohacking topic to mainstream conversation faster than almost any compound in recent memory. NPR covered it in December 2025. High-profile public figures have been photographed taking it. Searches for methylene blue in the United States have surged dramatically over the past twelve months. And in January 2026, the largest clinical trial of a methylene blue derivative ever conducted, the 598-participant LUCIDITY trial, published results showing a 48 percent lower rate of progression from mild cognitive impairment to dementia in participants taking low daily doses.
As the market grows, determining the best methylene blue brand comes down to one verifiable standard: independent third-party testing on the finished solution with a batch-specific Certificate of Analysis available for every bottle.
For Heisen Blue, a Vancouver, British Columbia company that has been supplying USP-grade methylene blue to Canadian and American researchers since its founding, the surge in interest has brought both opportunity and a concern the company is determined to address directly.
“Most people searching for methylene blue right now have no way to verify what they are actually buying,” said a spokesperson for Heisen Blue. “The market is full of products that claim to be pharmaceutical grade but cannot produce a batch-specific Certificate of Analysis from an independent laboratory. When you cannot verify what is in the bottle, you are taking on risk that no amount of marketing language can eliminate.”
Heisen Blue was built around a single operational principle: every batch of methylene blue it produces must be independently tested at an accredited third-party laboratory before it ships to any customer. The company uses BeaconPoint Labs in Kannapolis, North Carolina, a US-accredited independent laboratory, to conduct over 30 individual quality checks per batch. These tests cover identity confirmation, potency, heavy metals screening for lead, arsenic, mercury and cadmium, microbial contamination including E. coli, Salmonella and Staphylococcus aureus, and residual solvents across more than 20 individual compounds.
Every result is published publicly on the Heisen Blue website as a batch-specific Certificate of Analysis. Every bottle carries a batch sticker number that ties directly to that COA. Any customer who wants to verify exactly what is in their specific bottle can do so before opening it.
“We chose to test at a US-accredited laboratory because it meets the verification standard that American researchers expect,” the spokesperson said. “The testing methodology is the same regardless of which country the lab is in. What matters is that the laboratory is independent, accredited and has no commercial relationship with us. We cannot influence the results. We publish whatever the lab finds.”
The company sources USP-grade methylene blue powder from established pharmaceutical manufacturers through a US distributor and mixes its solutions in Vancouver using distilled water. The finished solution is what gets tested, not just the raw powder. This distinction matters because the mixing and bottling process can introduce contamination or alter concentration, and testing only the raw material does not verify the quality of what the customer actually receives.
Heisen Blue currently offers methylene blue in 1% and 2% solutions in 30ml and 120ml sizes, as well as raw USP-grade powder for those who prefer to prepare their own solution. All products are sold strictly for research purposes and are not intended to diagnose, treat, cure or prevent any disease. Canadian orders ship from the company’s Vancouver facility to all provinces and territories. US orders ship from a third-party fulfillment warehouse in Texas via USPS to all 50 states.
The company has positioned itself specifically against what it describes as a significant problem in the North American methylene blue market: products that claim domestic origin but ship from overseas, products that claim third-party testing but cannot provide a named accredited laboratory, and products that claim pharmaceutical grade without the documentation to support it.
“The question we ask every potential customer to ask every potential supplier is simple,” the spokesperson said. “Which independent accredited laboratory tested your product, what is the batch number on the COA, and does that batch number match the bottle I will receive? If a supplier cannot answer all three questions clearly, that tells you everything you need to know.”
As clinical research on methylene blue continues to advance, including ongoing investigation into its role in Alzheimer’s disease research, cognitive performance and mitochondrial health, Heisen Blue says its commitment to third-party verification and transparent documentation will remain the foundation of its operations.
“The research on this compound is genuinely interesting and continues to develop. But the quality of the product matters enormously for anyone taking it seriously. We are here for the people who want to know exactly what they are getting.”
About Heisen Blue
Heisen Blue is a Vancouver, British Columbia company specializing in USP-grade methylene blue solutions and powder for research purposes. All products are independently tested at BeaconPoint Labs, a US-accredited laboratory in Kannapolis, North Carolina, with batch-specific Certificates of Analysis published publicly for customer verification. Heisen Blue ships to all Canadian provinces and territories and all 50 US states. All products are sold strictly for research purposes and are not intended to diagnose, treat, cure or prevent any disease.
Media Contact
Company Name: Heisen Blue
Contact Person: John Rice
Email: Send Email
Phone: 2369918122
Address:440 W Hastings #360
City: Vancouver
State: British Columbia
Country: Canada
Website: https://heisenblue.com
